249 related articles for article (PubMed ID: 18000515)
1. Emerging biological therapies in systemic lupus erythematosus.
Mount GR; Gilliland WR
Clin Pharmacol Ther; 2008 Jan; 83(1):167-71. PubMed ID: 18000515
[TBL] [Abstract][Full Text] [Related]
2. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.
Eisenberg R; Albert D
Nat Clin Pract Rheumatol; 2006 Jan; 2(1):20-7. PubMed ID: 16932648
[TBL] [Abstract][Full Text] [Related]
3. Treating lupus: from serendipity to sense, the rise of the new biologicals and other emerging therapies.
Sousa E; Isenberg D
Best Pract Res Clin Rheumatol; 2009 Aug; 23(4):563-74. PubMed ID: 19591785
[TBL] [Abstract][Full Text] [Related]
4. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
[TBL] [Abstract][Full Text] [Related]
5. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.
Albert D; Dunham J; Khan S; Stansberry J; Kolasinski S; Tsai D; Pullman-Mooar S; Barnack F; Striebich C; Looney RJ; Prak ET; Kimberly R; Zhang Y; Eisenberg R
Ann Rheum Dis; 2008 Dec; 67(12):1724-31. PubMed ID: 18250115
[TBL] [Abstract][Full Text] [Related]
6. Use of rituximab in patients with systemic lupus erythematosus: an update.
García-Carrasco M; Jiménez-Hernández M; Escárcega RO; Mendoza-Pinto C; Galarza-Maldonado C; Sandoval-Cruz M; Zamudio-Huerta L; López-Colombo A; Cervera R
Autoimmun Rev; 2009 Feb; 8(4):343-8. PubMed ID: 19036350
[TBL] [Abstract][Full Text] [Related]
7. B cell targeted therapies in autoimmune diseases.
Isenberg DA
J Rheumatol Suppl; 2006 May; 77():24-8. PubMed ID: 16652442
[TBL] [Abstract][Full Text] [Related]
8. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
[TBL] [Abstract][Full Text] [Related]
9. New immunosuppressive therapies in renal transplantation: monoclonal antibodies.
Buhaescu I; Segall L; Goldsmith D; Covic A
J Nephrol; 2005; 18(5):529-36. PubMed ID: 16299678
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
Goldblatt F; Isenberg DA
Handb Exp Pharmacol; 2008; (181):163-81. PubMed ID: 18071946
[TBL] [Abstract][Full Text] [Related]
11. [Biological treatment of rare inflammatory rheumatic diseases].
Baslund B
Ugeskr Laeger; 2008 Jun; 170(24):2150-2. PubMed ID: 18565301
[TBL] [Abstract][Full Text] [Related]
12. Lupus: novel therapies in clinical development.
Chugh PK
Eur J Intern Med; 2012 Apr; 23(3):212-8. PubMed ID: 22385876
[TBL] [Abstract][Full Text] [Related]
13. Systemic lupus erythematosus.
Manson JJ; Rahman A
Orphanet J Rare Dis; 2006 Mar; 1():6. PubMed ID: 16722594
[TBL] [Abstract][Full Text] [Related]
14. [Molecular targets and their regulation in systemic lupus erythematosus and lupus nephritis].
Takasaki Y
Nihon Jinzo Gakkai Shi; 2012; 54(5):598-602. PubMed ID: 22991839
[No Abstract] [Full Text] [Related]
15. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus.
Yao Y; Richman L; Higgs BW; Morehouse CA; de los Reyes M; Brohawn P; Zhang J; White B; Coyle AJ; Kiener PA; Jallal B
Arthritis Rheum; 2009 Jun; 60(6):1785-96. PubMed ID: 19479852
[TBL] [Abstract][Full Text] [Related]
16. Systemic lupus erythematosus in children: current and emerging therapies.
Macdermott EJ; Adams A; Lehman TJ
Lupus; 2007; 16(8):677-83. PubMed ID: 17711907
[TBL] [Abstract][Full Text] [Related]
17. Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies.
Hutas G
Curr Opin Investig Drugs; 2008 Nov; 9(11):1206-15. PubMed ID: 18951300
[TBL] [Abstract][Full Text] [Related]
18. Target therapies in systemic lupus erythematosus: current state of the art.
Wiesik-Szewczyk E; Lacki JK; Feleszko W; Olesinska M
Mini Rev Med Chem; 2010 Sep; 10(10):956-65. PubMed ID: 21034417
[TBL] [Abstract][Full Text] [Related]
19. Belimumab: a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus.
Dennis GJ
Clin Pharmacol Ther; 2012 Jan; 91(1):143-9. PubMed ID: 22130121
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of infliximab in active SLE: a pilot study.
Uppal SS; Hayat SJ; Raghupathy R
Lupus; 2009 Jul; 18(8):690-7. PubMed ID: 19502264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
